Prof. George Bakris and prof. Giuseppe Rosano examine the management of hyperkalemia in patients with HF and CKD, and provide individualized approaches for optimizing RAASi therapy. Collaboration between nephrologists and cardiologists is key, according to the discussants.
Prof. Lam talks about effects of SGLT2i in HF across the spectrum of LVEF and reviews current guideline treatment recommendations.
Javed Butler and Shelley Zieroth talk about the effects and tolerability of SGLT2i and the oral soluble guanylate cyclase stimulator vericiguat in patients with HFrEF.
Managing hyperkalemia while optimizing RAASi therapy in patients with heart failure can be challenging. Andrew Coats talks about this clinical dilemma.
Prof. McMurray talks about barriers and concerns regarding initiating guideline recommended therapy in patients with heart failure.
Ileana Piña, Javed Butler, Marco Metra and Giuseppe Rosano talk about ESC/HFA guideline updates, management strategies for recurrent hyperkalemia, and foundational therapy for patients with heart failure.
Smoking is an important modifiable risk factor for HF. But to what extent does this apply to the 2 phenotypes of HF: HFrEF and HFpEF? And what is the effect of (long-term) smoking cessation? A recent analysis of the ARIC study offers valuable insights.
Javed Butler and Piotr Ponikowski discuss the clinical significance of iron deficiency in patients with HFrEF, and take a close look at the key updates in the 2021 ESC/HFA guidelines.
Gregg Fonarow and Andrew Coats review the key updates in the latest ESC/HFA heart failure guidelines and talk about strategies for maintaining optimal RAASi therapy in patients with heart failure and multiple comorbidities.
ESC Heart Failure 2022 An analysis of the EMPULSE trial investigated the decongestive effects of empagliflozin compared with placebo in addition to standard medical treatment.
ESC Heart Failure 2022 A randomized clinical trial investigated the effect of dapagliflozin on maximal functional capacity at 1 and 3 months in patients with stable HFrEF.
ESC Heart Failure 2022 In the DIAMOND trial, use of patiromer not only resulted in maintenance of lower levels of potassium compared with placebo, but also in a lower risk of hyperkalemia events in HFrEF patients on RAASi therapy.